Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dell Technologies Inc (DELL) vs Viatris Inc (VTRS) Price & Performance

Dell Technologies IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Dell Technologies Inc vs Viatris Inc — how do they compare? Dell Technologies Inc trades at $481.6 (market cap $284.93B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Dell Technologies Inc is far larger — about 15.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.

DELLVTRS
Market Cap
$284.93B$18.69B
Sector
TechnologyHealth
52-Week High
$467.27$17.86
52-Week Low
$111.10$9.49
Enterprise Value
$304.51B$30.80B
Dividend Yield
0.57%2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dell Technologies Inc

Dell Technologies stock trades at $478.30, up 4.45% in the last session, reflecting strong momentum amid AI-driven server demand. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $4.86 surpassing the $2.96 forecast. The technical outlook is bullish, with the price above key moving averages, while fundamentals show revenue growth to $95.57 billion in 2025 and a net income margin of 6.28%.

The outlook remains positive given robust analyst sentiment, with a consensus price target of $503.76 implying upside. Key risks include valuation concerns at a P/E of 35.14 and potential margin pressure from memory shortages. Continued execution on AI server backlog and commercial PC refresh cycles are critical for sustained growth.

Viatris Inc

Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.

Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dell Technologies Inc

VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses

Read more on DELL

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS